MaryAnn Go
YOU?
Author Swipe
View article: Supplementary Figure 4 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
Supplementary Figure 4 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma Open
PDF file - 48KB, In vivo efficacy of anti-FcRL5-MC-vc-PAB-MMAE in combination with lenalidomide
View article: Supplementary Figure 1 from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma
Supplementary Figure 1 from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma Open
PDF file - 61K, Supplemental Figure 1. Human, cynomolgus monkey, and rat PBMCs were isolated from whole blood in accordance with BD Vacutainer CPT protocol. Mouse PBMCs were isolated from whole blood by ACK lysis buffer treatment to lyse…
View article: Supplementary Figure 2 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
Supplementary Figure 2 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma Open
PDF file - 62KB, In vivo efficacy of anti-FcRL5-SPDB-DM4 in combination with bortezomib
View article: Data from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma
Data from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma Open
Antibody–drug conjugates (ADC), potent cytotoxic drugs linked to antibodies via chemical linkers, allow specific targeting of drugs to neoplastic cells. We have used this technology to develop the ADC DCDT2980S that targets CD22, an antige…
View article: Data from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
Data from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma Open
Fc receptor-like 5 (FcRL5/FcRH5/IRTA2/CD307) is a surface protein expressed selectively on B cells and plasma cells. We found that FcRL5 was expressed at elevated levels on the surface of plasma cells from the bone marrow of patients diagn…
View article: Supplementary Figure 4 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
Supplementary Figure 4 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma Open
PDF file - 48KB, In vivo efficacy of anti-FcRL5-MC-vc-PAB-MMAE in combination with lenalidomide
View article: Supplementary Figure 2 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
Supplementary Figure 2 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma Open
PDF file - 62KB, In vivo efficacy of anti-FcRL5-SPDB-DM4 in combination with bortezomib
View article: Data from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma
Data from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma Open
Antibody–drug conjugates (ADC), potent cytotoxic drugs linked to antibodies via chemical linkers, allow specific targeting of drugs to neoplastic cells. We have used this technology to develop the ADC DCDT2980S that targets CD22, an antige…
View article: Supplementary Figure 1 from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma
Supplementary Figure 1 from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma Open
PDF file - 61K, Supplemental Figure 1. Human, cynomolgus monkey, and rat PBMCs were isolated from whole blood in accordance with BD Vacutainer CPT protocol. Mouse PBMCs were isolated from whole blood by ACK lysis buffer treatment to lyse…
View article: Supplementary Figure Legends from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
Supplementary Figure Legends from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma Open
PDF file - 25KB
View article: Data from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
Data from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma Open
Fc receptor-like 5 (FcRL5/FcRH5/IRTA2/CD307) is a surface protein expressed selectively on B cells and plasma cells. We found that FcRL5 was expressed at elevated levels on the surface of plasma cells from the bone marrow of patients diagn…
View article: Supplementary Figure 3 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
Supplementary Figure 3 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma Open
PDF file - 48KB, In vivo efficacy of anti-FcRL5-MC-vc-PAB-MMAE in combination with bortezomib
View article: Supplementary Figure 1 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
Supplementary Figure 1 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma Open
PDF file - 282KB, In vivo efficacy of anti-FcRL5 ADCs with different linker-drugs
View article: Supplementary Table 1 from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma
Supplementary Table 1 from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma Open
XLSX file - 30K, IC50 concentrations and CD22 expression levels for cell lines.
View article: Supplementary Figure 3 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
Supplementary Figure 3 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma Open
PDF file - 48KB, In vivo efficacy of anti-FcRL5-MC-vc-PAB-MMAE in combination with bortezomib
View article: Supplementary Figure 1 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
Supplementary Figure 1 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma Open
PDF file - 282KB, In vivo efficacy of anti-FcRL5 ADCs with different linker-drugs
View article: Supplementary Table 1 from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma
Supplementary Table 1 from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma Open
XLSX file - 30K, IC50 concentrations and CD22 expression levels for cell lines.
View article: Supplementary Figure Legends from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
Supplementary Figure Legends from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma Open
PDF file - 25KB
View article: Data from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
Data from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs Open
Purpose: We are interested in identifying mechanisms of resistance to the current generation of antibody–drug conjugates (ADC) and developing ADCs that can overcome this resistance.Experimental Design: Pinatuzumab vedotin (an…
View article: Supplementary 4 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
Supplementary 4 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs Open
Supplementary 4. P-gp overexpressing BJAB.Luc cell line showed the similar resistance to anti-CD22-vc-MMAE
View article: Supplementary 2 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
Supplementary 2 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs Open
Supplementary 2. In vivo efficacy of anti-CD22-vc-MMAE and anti-CD22-SPDB-DM4
View article: Data from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
Data from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs Open
Purpose: We are interested in identifying mechanisms of resistance to the current generation of antibody–drug conjugates (ADC) and developing ADCs that can overcome this resistance.Experimental Design: Pinatuzumab vedotin (an…
View article: supplemental figure legend from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
supplemental figure legend from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs Open
supplemental figure legend
View article: Supplementary 4 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
Supplementary 4 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs Open
Supplementary 4. P-gp overexpressing BJAB.Luc cell line showed the similar resistance to anti-CD22-vc-MMAE
View article: Supplementary 1 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
Supplementary 1 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs Open
Supplementary 1. In vivo efficacy of anti-CD22-vc-MMAE
View article: Supplementary 3 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
Supplementary 3 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs Open
Supplementary 3. Cell lines derived from xenograft tumors resistant to anti-CD22-vc-MMAE were resistance to anti-CD22-vc-MMAE
View article: supplemental figure legend from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
supplemental figure legend from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs Open
supplemental figure legend
View article: Supplementary 1 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
Supplementary 1 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs Open
Supplementary 1. In vivo efficacy of anti-CD22-vc-MMAE
View article: Supplementary 3 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
Supplementary 3 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs Open
Supplementary 3. Cell lines derived from xenograft tumors resistant to anti-CD22-vc-MMAE were resistance to anti-CD22-vc-MMAE
View article: Supplementary 2 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
Supplementary 2 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs Open
Supplementary 2. In vivo efficacy of anti-CD22-vc-MMAE and anti-CD22-SPDB-DM4